- Coya Therapeutics (COYA, Financial) reports a 42% increase in regulatory T cell (Treg) suppressive function with COYA 303.
- Combination of low-dose interleukin 2 and GLP-1 receptor agonist shows promising results in autoimmune and neurodegenerative diseases.
- COYA 303 shows potential application in conditions like Alzheimer's Disease.
Coya Therapeutics, Inc. (COYA), a clinical-stage biotechnology company, announced significant findings from its recent study on the investigational biologic COYA 303. This novel combination treatment, comprising low-dose interleukin 2 (LD IL-2) and GLP-1 receptor agonist (GLP-1RA), demonstrated a 42% enhancement in the suppressive function of regulatory T cells (Tregs), far surpassing the effects of the individual components, LD IL-2 and GLP-1RA, which showed improvements of 15% and 20%, respectively.
Conducted at the Houston Methodist Research Institute, the study highlights COYA 303's ability to enhance Treg survival by modulating the apoptotic pathway, specifically through the reduction of BAX transcript levels. This dual-action mechanism not only augments Treg function but also aids in Treg survival in inflammatory conditions, potentially offering a new approach for neurodegenerative and autoimmune diseases such as Alzheimer's.
Dr. Arun Swaminathan, Coya's CEO, emphasized the differentiated approach of COYA 303 in addressing conditions with significant unmet needs by combining anti-inflammatory and immunomodulatory effects. The study's positive results suggest that COYA 303 may represent a significant value-creating opportunity within the GLP-1RA therapeutic class.
While these findings present a promising step forward for COYA 303, they remain at an early stage, with clinical validation yet to be established. The publication of these results in a peer-reviewed journal reflects Coya's commitment to developing novel therapeutics aimed at restoring Treg function across various disease areas.
